Healthcare Industry News: Radixact
News Release - June 20, 2017
IUCT Oncopole Advances Cancer Care in France with the New Accuray Radixact(TM) SystemThe French Cancer Institute is Building its Re-irradiation and Adaptive Radiotherapy Program Using the Latest Technology Developed by Accuray
SUNNYVALE, Calif., June 20, 2017 -- (Healthcare Sales & Marketing Network) -- Accuray Incorporated (NASDAQ: ARAY) announced today that the University Cancer Institute of Toulouse Oncopole (IUCT Oncopole) is providing advanced radiation treatments to cancer patients using the uniquely smart Radixact™ Treatment Delivery System, the first to be installed in France. The IUCT Oncopole began treating patients in January with this new system, designed to deliver image-guided intensity-modulated radiation therapy (IG-IMRT), an extremely precise form of radiation therapy.
"The acquisition of innovative equipment, including the Radixact System, is part of our strategy to offer best-in-class cancer care to all patients in the region," said Professor Elizabeth Moyal, Head of the Radiotherapy Department at the IUCT Oncopole. "What makes the Radixact technology so special is that its sophisticated tools enable us to use progressive clinical approaches such as re-irradiation and adaptive therapy to ensure patients receive the optimal treatment for them, at every stage of their cancer journey."
The benefits of the Radixact System: an innovative technology created to empower clinicians to improve their patients' care
The Radixact System is the next generation TomoTherapy® platform. Fully integrated with the Accuray Precision™ Treatment Planning System and the iDMS™ Data Management System, the system enables clinicians to achieve the best possible treatment outcomes today and for years to come.
The Radixact System has been designed to facilitate faster image acquisition and treatment delivery, allowing the clinical team to provide precise radiation treatments to more patients, every day. The system features a more powerful linear accelerator, low-dose fan beam MVCT imaging and unique helical delivery technology, so clinicians can apply highly conformal and homogenous dose distributions to any target volume, while minimizing dose to surrounding normal healthy tissue, during each treatment fraction. Smart, automated workflows and midcourse decision-making tools enable clinicians to adapt delivery to changes in tumor size, shape and location within the patient.
The Radixact System is capable of treating all standard radiation therapy indications such as brain, breast, head and neck, prostate, and rectal and spine cancers, in addition to complex treatments such as total marrow irradiation. It is so precise that, should the cancer re-occur, the patient can be re-treated on the Radixact System. As explained by Prof. Moyal, "We have successfully administered treatment for several types of cancers so far including breast cancer, head and neck cancers, and pediatric tumors which we previously treated on a routine basis using the TomoTherapy System. Moving forward we plan to use the Radixact System to provide treatment for abdominal, hematologic and pelvic tumors, indications which will also benefit from the system's advanced adaptive therapy capabilities."
"We are very proud to partner with IUCT Oncopole to enhance the quality of care for cancer patients in France. Prof. Moyal and her team are demonstrating that the Radixact™ System can successfully be used as a mainstream radiation therapy option, enabling them to provide effective treatments for patients with a diverse range of clinical needs," says Lionel Hadjadjeba, Senior Vice President, and Chief Commercial Officer at Accuray.
About the University Cancer Institute of Toulouse Oncopole (IUCT Oncopole)
The IUCT Oncopole is comprised of the Institut Claudius Regaud, a cancer center, and several teams from Toulouse University Hospital Center. The two institutions offer the expertise of 1,400 professionals specialized in oncology on the same site. Located in the heart of a campus grouping together public and private stakeholders, it is involved in the fight against cancer. Indeed, the IUCT Oncopole is a new way to think of cancer healthcare. To the healthcare and public health missions of this property is added a top priority: Innovation and research for the benefit of the patient.
The IUCT Oncolope gathers all the oncological specialties required to detect, treat, and monitor disease: surgery, medicine, radiotherapy and brachytherapy, nuclear medicine, interventional imaging, biology and anatomical pathology. Its Radiotherapy Department, that treats 3,000 patients annually, is led by Prof. Elizabeth Moyal. It is equipped with 7 accelerators, including 2 TomoTherapy® Systems and one Radixact System.
Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology company that develops, manufactures and sells precise, innovative tumor treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit www.accuray.com.
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to clinical applications, clinical results, patient experiences and outcomes, and Accuray's leadership position in radiation oncology innovation and technologies. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to the risks detailed from time to time under the heading "Risk Factors" in the company's report on Form 10-K, filed on August 24, 2016, the company's reports on Form 10-Q, filed on November 1, 2016 and February 3, 2017, and May 5, 2017, and as updated periodically with the company's other filings with the SEC.
Forward-looking statements speak only as of the date the statements are made and are based on information available to Accuray at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsAccuray and Limbus AI Inc. Partner to Leverage Limbus' Innovative AI-driven Technology to Enhance Accuray Adaptive Radiotherapy Solutions
Accuray Appoints Sandeep Chalke as SVP, Chief Commercial Officer
10-Year Data Shows Accuray CyberKnife(R) System Provides Long-Lasting Relief of the Excruciating Pain Caused by Trigeminal Neuralgia